Dr. Andreadis on CAR T-Cell Therapy for Pediatric ALL

Charalambos (Babis) Andreadis, MD, MSCE
Published: Friday, Dec 29, 2017



Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphoblastic leukemia (ALL).

According to Andreadis, pediatric ALL is largely curable with available treatments. However, there is a subset of patients who do not do well with frontline therapy. Those patietns are now seeing responses with CAR T-cell therapy.

There are still problems with the longevity of response, explains Andreadis. It is not clear which patients will benefit from subsequent stem cell transplant versus being monitored once they respond to CAR T-cell therapy.
 


Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphoblastic leukemia (ALL).

According to Andreadis, pediatric ALL is largely curable with available treatments. However, there is a subset of patients who do not do well with frontline therapy. Those patietns are now seeing responses with CAR T-cell therapy.

There are still problems with the longevity of response, explains Andreadis. It is not clear which patients will benefit from subsequent stem cell transplant versus being monitored once they respond to CAR T-cell therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x